^
    2d
    Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET (clinicaltrials.gov)
    P3, N=379, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2028 --> Mar 2026
    Trial completion • Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • vincristine • Neupogen (filgrastim)
    3d
    PM1183-C-010-22: Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with Metastatic Leiomyosarcoma (2022-502975-45-00)
    P2/3, N=345, Active, not recruiting, Pharma Mar S.A. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    doxorubicin hydrochloride • dexamethasone • Zepzelca (lurbinectedin) • Neupogen (filgrastim) • ondansetron
    3d
    Gineco-ov133b: REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy. (2025-524232-20-00)
    P1/2, N=43, Not yet recruiting, Asso De Recherche Cancers Gynecologiques
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018) • Neupogen (filgrastim)
    5d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    9d
    Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • Neupogen (filgrastim) • Orencia (abatacept)
    10d
    EA8192: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (clinicaltrials.gov)
    P2/3, N=131, Recruiting, National Cancer Institute (NCI) | N=249 --> 131
    Enrollment change
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • methotrexate IV
    12d
    Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=2, Terminated, Northwestern University | Active, not recruiting --> Terminated; Low accrual
    Trial termination
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH1 R132
    |
    cytarabine • Tibsovo (ivosidenib) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    19d
    Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • idarubicin hydrochloride • Scemblix (asciminib) • fludarabine IV • Neupogen (filgrastim)
    19d
    Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • Neupogen (filgrastim) • dexrazoxane
    29d
    Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    Neupogen (filgrastim) • plerixafor
    29d
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=66, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> May 2028 | Trial primary completion date: Nov 2027 --> May 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor